Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Allogene Therapeutics
Deal Size : $85.0 million
Deal Type : Series A Financing
Details : Financing supports advancement of initial T cell-based pipeline for cancer and expanded development of Engineered Thymic Niche (ETN) platform for multiple immune cell types.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Allogene Therapeutics
Deal Size : $85.0 million
Deal Type : Series A Financing
Reset All
